Replication FailureOpen accessMedicine· cited by 9

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

Domenica Lorusso; Laurence Gladieff; David M O'Malley; Jae-Weon Kim; Gabriel Garbaos; Anna Fagotti; Lucy Gilbert; Linda Mileshkin · 2026 · The Lancet

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: Relacorilant is a selective glucocorticoid receptor antagonist that increases the sensitivity of many cancer cell types to chemotherapy. The efficacy and safety of relacorilant plus nab-paclitaxel were assessed in the phase 3 ROSELLA (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) trial; the combination showed significant improvement in progression-free survival among patients with platinum-resistant ovarian cancer compared with nab-paclitaxel monotherapy. Results of the final overall survival analysis are reported here. METHODS: intravenously on the aforementioned schedule). Pa

Abstract by Domenica Lorusso; Laurence Gladieff; David M O'Malley; Jae-Weon Kim; Gabriel Garbaos; Anna Fagotti; Lucy Gilbert; Linda Mileshkin, The Lancet (2026) — licensed CC BY 4.0.

Read the full paper (open access)